GRAIL, Inc.
corporate_fare Company Profile
GRAIL, Inc. (NASDAQ:GRAL) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 19 items for GRAL at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-05, rated 7/10. Across its 19 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for GRAL spans 10-Q, 144, 8-K, DEF 14A.
Recent high-impact activity:
- GRAIL Q3: Galleri Revenue Up 14% to $37.3M, Net Loss Widens to $103.6M
- Galleri Revenue Up 14% but Net Loss Widens to $103.6M; FDA Decision Due Early Q1 2027
- FDA Panel Backs GRAIL's Galleri Cancer Test, Clearing Key Hurdle
- Grail Trading Halted Ahead of FDA AdCom on Galleri Blood Test
- GRAIL CEO Joshua Ofman Files to Sell 71,452 Shares Worth $5.77M
Financial Snapshot
Short Interest & Short Volume
8.70 days to coverFINRA reported short interest of 7,998,817 shares in GRAL as of the October 30, 2026 settlement, a 2.1% decrease from the prior period — about 8.7 days to cover at its recent average daily volume. On November 20, 2026, 74.3% of GRAL volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.